Neuromodulation Market by Type (Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation)), Application (Parkinson's Disease, Depression, Urine incontinence, Epilepsy, Obesity) - Global Forecast to 2027
The global neuromodulation market in terms of revenue was estimated to be worth $6.0 billion in 2022 and is poised to reach $10.4 billion by 2027, growing at a CAGR of 11.8% from 2022 to 2027. Market growth is driven by the high adoption of innovative neuromodulation devices among medical professionals, and the wide availability of advanced neuromodulation devices.
To know about the assumptions considered for the study, Request for Free Sample Report
Neuromodulation Market Dynamics
Drivers: Growing prevalence neurological disorders and nerve injuries to increase demand for neuromodulation
It is estimated that about a billion individuals suffer from neurological disorders globally, and ~6.8 million die every year (Source: WHO). Sports injuries also contribute significantly to nerve injuries. According to the Brain Injury Research Institute, over 1.6 million to 3.8 million athletes suffer concussions annually. Neuromodulation techniques, such as deep brain stimulation, spinal cord stimulation, and transcutaneous electrical nerve stimulation, are used to treat patients suffering from such neurological diseases and nerve injuries. Thus, the high incidence rates of neurological disorders and nerve injuries will increase the demand for neuromodulation devices in the future.
Challenges: Preference of drug therapies over neuromodulation products challenge the neuromodulation market growth
Patients often prefer drug therapies over neuromodulation for treating neurological disorders. This is because of limited patient awareness about the availability of alternative surgical treatments that use neuromodulation devices. This lack of awareness is also evident in surgeons in some countries. For instance, overactive bladder (OAB) syndrome remains untreated in many individuals across the globe due to a lack of awareness about effective treatment options, such as sacral nerve stimulation. Thus, the lack of awareness about the benefits of using biomaterials or neuromodulation devices to treat several neurological disorders is expected to restrain the growth of this market during the forecast period.
Restraints: High cost of neuromodulation procedures a key restraining factor holding back growth of market
The high cost of neuromodulation procedures and devices is a major factor restraining the growth of the global neuromodulation market, especially in developing countries with poor reimbursement policies. The average cost of a standard implantable pulse generator is ~USD 10,000–15,000; implantation procedures can cost as high as USD 25,000–35,000. Spinal cord stimulator devices cost around USD 13,000–40,000. Owing to high costs and a poor reimbursement scenario, a very limited pool of patients in developing countries can afford neurological treatment. As a result, healthcare facilities are reluctant to invest in new or technologically advanced systems, thus limiting the growth of the neuromodulation market.
Neuromodulation Market Ecosystem
“In 2021, internal neuromodulation segment accounted for the largest share of the neuromodulation market, by type”
The global neuromodulation market is segmented into internal and external neuromodulation based on product. Market growth is largely driven by the benefits of internal neuromodulation procedures, such as reduced post-surgical complications, shorter hospitalizations, and improved quality of life.
“In 2021, spinal cord stimulation segment accounted for the largest share in the internal neuromodulation market, by type”
The internal neuromodulation market is segmented into spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS), and gastric electrical stimulation (GES) by type. The spinal cord stimulation segment accounted for the largest share owing to the increasing number of people suffering from FBSS (failed back surgery syndrome), ischemia, and chronic pain and the favorable reimbursement scenario for spinal cord stimulation devices.
“In 2021, transcutaneous electrical nerve stimulation segment accounted for the largest share in the external neuromodulation market, by type”
The external neuromodulation market is segmented into transcutaneous electrical nerve stimulation (TENS), transcranial magnetic stimulation (TMS), and respiratory electrical stimulation (RES). In 2021, transcutaneous electrical nerve stimulation accounted for the largest share of the neuromodulation market. This can be attributed as they are inexpensive, easily available to end users, and can be self-administered. The lack of stringent regulations for these devices is also propelling their growth.
“In 2021, North America accounted for the largest share of the neuromodulation market ”
The global neuromodulation market is segmented into four major regions namely, North America, Europe, the Asia Pacific, and Rest of the World. North America accounted for the largest share of the neuromodulation market in 2021. Factors such as the highly developed healthcare system, and the large number of manufacturing companies are contributing to the large share of this regional segment.
To know about the assumptions considered for the study, download the pdf brochure
The neuromodulation market is dominated by players such as Medtronic plc (Ireland), Boston Scientific Corporation (US), and Abbott Laboratories (US).
Neuromodulation Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2022 |
$6.0 billion |
|
Estimated Value by 2027 |
$10.4 billion |
|
Growth Rate |
poised to grow at a CAGR of 11.8% |
|
Largest Share Segments |
Internal neuromodulation, Spinal cord stimulation & transcutaneous electrical nerve stimulation |
|
Market Report Segmentation |
Type, Application & Region |
|
Growth Drivers |
|
|
Growth Opportunities |
|
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
This report categorizes the neuromodulation market into the following segments and subsegments:
By Type
-
Internal Neuromodulation
- Spinal Cord Stimulation
- Deep Brain Stimulation
- Vagus Nerve Stimulation
- Sacral Nerve Stimulation
- Gastric Electrical Stimulation
-
External Neuromodulation
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Transcranial Magnetic Stimulation (TMS)
- Respiratory Electrical Stimulation (RES)
By Application
-
Spinal Cord Stimulation Market, By Application
- Failed Back Syndrome
- Chronic Pain
- Ischemia
-
Deep Brain Stimulation Market, By Application
- Parkinson’s Disease
- Tremor
- Depression
- Other DBS Applications
-
Sacral Nerve Stimulation Market, By Application
- Urine Incontinence
- Fecal Incontinence
-
Vagus Nerve Stimulation Market, By Application
- Epilepsy
- Other VNS Applications
-
Gastric Electrical Stimulation Market, By Application
- Gastroparesis
- Obesity
-
Transcutaneous Electrical Nerve Stimulation Market, By Applicatio
- Treatment-resistant Depression
- Other TENS Applications
-
Transcranial Magnetic Stimulation Market, By Application
- Depression
- Migraine Headache
-
Respiratory Electrical Stimulation Market, By Application
- Spinal Cord Injury
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Rest of the World
Recent Developments
- In February 2022, Medtronic (Ireland) received FDA approval for its InterStim X System, a next-generation personalized sacral nerve stimulation therapy for bladder and bowel control.
- In June 2021, NeuroSigma (US) and KT Corporation (South Korea) signed a memorandum of understanding for a strategic partnership to develop and commercialize, inside and outside of Korea, electronic therapies treating neurological and neuropsychological disorders, including ADHD, depression, and epilepsy.
- In February 2020, LivaNova Plc (UK) signed a research collaboration with Verily (US), an Alphabet company, to capture measures of depression within its RECOVER clinical study. The study evaluates the effectiveness of vagus nerve stimulation therapy for difficult-to-treat depression (DTD).
- In January 2020, Medtronic Plc (Ireland) acquired Stimgenics, LLC (US), a privately held US-based company. This acquisition helped strengthen Medtronic’s portfolio of spinal cord stimulation systems.
Frequently Asked Questions (FAQs):
What is the size of Neuromodulation Market ?
The global neuromodulation market boasts a total value of $6.0 billion in 2022 and is projected to register a growth rate of 11.8% to reach a value of $10.4 billion by 2027.
Why is Neuromodulation Market Growing?
Market growth is driven by the high adoption of innovative neuromodulation devices among medical professionals, and wide availability of advanced neuromodulation devices.
Who all are the prominent players of Neuromodulation Market ?
The neuromodulation market is dominated by players such as Medtronic plc (Ireland), Boston Scientific Corporation (US), and Abbott Laboratories (US) .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 32)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 NEUROMODULATION MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 36)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
TABLE 1 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 4 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS
2.6 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: NEUROMODULATION MARKET
2.7 LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 47)
FIGURE 7 NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 8 INTERNAL NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 9 EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 10 NEUROMODULATION MARKET: GEOGRAPHIC SNAPSHOT
4 PREMIUM INSIGHTS (Page No. - 50)
4.1 NEUROMODULATION MARKET OVERVIEW
FIGURE 11 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE GROWTH IN NEUROMODULATION MARKET
4.2 NORTH AMERICA: NEUROMODULATION MARKET, BY TYPE & COUNTRY (2021)
FIGURE 12 INTERNAL NEUROMODULATION ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021
4.3 GEOGRAPHIC GROWTH OPPORTUNITIES IN NEUROMODULATION MARKET
FIGURE 13 COUNTRIES IN ASIA PACIFIC TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 52)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 14 NEUROMODULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of neurological disorders and nerve injuries
5.2.1.2 Growing focus on neuromodulation & neurostimulation technologies
5.2.1.3 Expanding applications of neuromodulation
TABLE 3 INDICATIVE LIST OF NEUROMODULATION CLINICAL TRIALS
FIGURE 15 RESEARCH PAPERS PUBLISHED (2011–2021)
5.2.1.4 Growing geriatric population and subsequent increase in prevalence of neurological disorders
5.2.1.5 Government support for research on neurological disorders
FIGURE 16 FUNDING FOR RESEARCH BY NIH (US)
5.2.2 RESTRAINTS
5.2.2.1 High cost of neuromodulation procedures
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging economies
FIGURE 17 GROWTH IN CURRENT PER CAPITA HEALTHCARE EXPENDITURE, 2012–2019
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory frameworks and time-consuming approval processes
5.2.4.2 Preference for drug therapies over neuromodulation products
5.2.4.3 Shortage of trained professionals
5.2.4.4 Product recalls
TABLE 4 MAJOR PRODUCT RECALLS
5.3 SCENARIO-BASED MARKET ASSESSMENT
5.3.1 NEUROMODULATION MARKET
FIGURE 18 PESSIMISTIC SCENARIO
FIGURE 19 OPTIMISTIC SCENARIO
FIGURE 20 REALISTIC SCENARIO
5.4 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
5.4.1 RESEARCH & DEVELOPMENT
5.4.2 MANUFACTURING & ASSEMBLY
5.4.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 22 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.6 TECHNOLOGY ANALYSIS
5.7 PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT FROM NEW ENTRANTS
5.7.2 INTENSITY OF COMPETITIVE RIVALRY
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 THREAT FROM SUBSTITUTES
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
5.8.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON THE BUYING PROCESS, BY TECHNOLOGY
TABLE 5 INFLUENCE OF STAKEHOLDERS ON THE BUYING PROCESS FOR THE TOP 3 TECHNOLOGIES (%)
5.8.2 BUYING CRITERIA
FIGURE 24 KEY BUYING CRITERIA FOR TOP 2 END USERS
TABLE 6 KEY BUYING CRITERIA, BY END USER
5.9 REGULATORY LANDSCAPE
TABLE 7 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING NEUROMODULATION
5.9.1 BY REGION
5.9.1.1 North America
5.9.1.2 Europe
5.9.1.3 Asia Pacific
5.9.1.3.1 India
5.9.1.3.2 China
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES AND EVENTS IN 2022
TABLE 8 LIST OF CONFERENCES & EVENTS
5.12 PRICING ANALYSIS
TABLE 9 PRICE RANGE FOR NEUROMODULATION DEVICES AND PROCEDURES
5.13 TRADE ANALYSIS
TABLE 10 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 11 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016–2020 (USD MILLION)
5.14 ECOSYSTEM ANALYSIS
5.14.1 ROLE IN ECOSYSTEM
5.14.2 KEY PLAYERS IN THE NEUROMODULATION MARKET
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
6 NEUROMODULATION MARKET, BY TYPE (Page No. - 75)
6.1 INTRODUCTION
TABLE 12 NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2 INTERNAL NEUROMODULATION
TABLE 13 INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 14 INTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 15 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 16 EUROPE: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 17 ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 18 REST OF THE WORLD: INTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.1 SPINAL CORD STIMULATION
6.2.1.1 Growing incidence of spinal cord injuries to support market growth
TABLE 19 SPINAL CORD STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 20 SPINAL CORD STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
TABLE 21 NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 22 EUROPE: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 23 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 24 REST OF THE WORLD: SPINAL CORD STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.2 DEEP BRAIN STIMULATION
6.2.2.1 DBS allows stimulation parameters to be changed to reduce side effects
TABLE 25 DEEP BRAIN STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 26 DEEP BRAIN STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
TABLE 27 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 28 EUROPE: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 29 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 30 REST OF THE WORLD: DEEP BRAIN STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.3 VAGUS NERVE STIMULATION
6.2.3.1 Non-invasive vagus nerve stimulation does not require surgical implantation—a key benefit
TABLE 31 VAGUS NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 32 VAGUS NERVE STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
TABLE 33 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 34 EUROPE: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 36 REST OF THE WORLD: VAGUS NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.4 SACRAL NERVE STIMULATION
6.2.4.1 Widening scope of sacral nerve stimulation to drive growth
TABLE 37 SACRAL NERVE STIMULATION DEVICES OFFERED
TABLE 38 SACRAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 39 SACRAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
TABLE 40 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 41 EUROPE: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 42 ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 43 REST OF THE WORLD: SACRAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.5 GASTRIC ELECTRICAL STIMULATION
6.2.5.1 Growing number of people suffering from severe GERD and gastroparesis to fuel market growth
TABLE 44 GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 45 GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
TABLE 46 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 47 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 REST OF THE WORLD: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 EXTERNAL NEUROMODULATION
TABLE 50 EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 51 EXTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 52 NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 EUROPE: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 54 ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 55 REST OF THE WORLD: EXTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION
6.3.1.1 Extensive use in healthcare, low cost, and ease of use to favor market growth
TABLE 56 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 57 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
TABLE 58 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 59 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 60 ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 61 REST OF THE WORLD: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.2 TRANSCRANIAL MAGNETIC STIMULATION
6.3.2.1 Minimal patient discomfort associated with TMS supports demand
TABLE 62 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 63 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
TABLE 64 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 65 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 66 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 67 REST OF THE WORLD: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.3 RESPIRATORY ELECTRICAL STIMULATION
6.3.3.1 High treatment efficacy to fuel market growth
TABLE 68 RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 69 RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
TABLE 70 NORTH AMERICA: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 71 EUROPE: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 72 ASIA PACIFIC: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 73 REST OF THE WORLD: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
7 NEUROMODULATION MARKET, BY APPLICATION (Page No. - 102)
7.1 INTRODUCTION
7.2 SPINAL CORD STIMULATION MARKET, BY APPLICATION
TABLE 74 SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.2.1 CHRONIC PAIN
7.2.1.1 High incidence of chronic pain supports market growth
TABLE 75 SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY REGION, 2020–2027 (USD MILLION)
7.2.2 FAILED BACK SURGERY SYNDROME
7.2.2.1 Growing incidence of FBSS due to rising number of surgeries each year to drive demand for stimulation technologies
TABLE 76 SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY REGION, 2020–2027 (USD MILLION)
7.2.3 ISCHEMIA
7.2.3.1 High effectiveness of neuromodulation for ischemia treatment to support market growth
TABLE 77 SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY REGION, 2020–2027 (USD MILLION)
7.3 DEEP BRAIN STIMULATION MARKET, BY APPLICATION
TABLE 78 DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.3.1 PARKINSON’S DISEASE
7.3.1.1 Rising incidence of Parkinson’s disease and growing R&D activity in this area to drive growth
TABLE 79 DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY REGION, 2020–2027 (USD MILLION)
7.3.2 TREMORS
7.3.2.1 High efficacy of DBS in treating tremors boosts demand
TABLE 80 DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY REGION, 2020–2027 (USD MILLION)
7.3.3 DEPRESSION
7.3.3.1 Lack of evidence of efficacy of DBS for depression treatment to limit market growth
TABLE 81 DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY REGION, 2020–2027 (USD MILLION)
7.3.4 OTHER DBS APPLICATIONS
TABLE 82 DEEP BRAIN STIMULATION MARKET FOR OTHER DBS APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
7.4 SACRAL NERVE STIMULATION MARKET, BY APPLICATION
TABLE 83 SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.4.1 URINE INCONTINENCE
7.4.1.1 High incidence of urine incontinence offers growth opportunities
TABLE 84 SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY REGION, 2020–2027 (USD MILLION)
7.4.2 FECAL INCONTINENCE
7.4.2.1 Reduced symptom recurrence supports use of SNS in fecal incontinence treatment
TABLE 85 SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY REGION, 2020–2027 (USD MILLION)
7.5 VAGUS NERVE STIMULATION MARKET, BY APPLICATION
TABLE 86 VAGUS NERVE MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.5.1 EPILEPSY
7.5.1.1 Advantages associated with VNS in epilepsy treatment to propel market
TABLE 87 VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY REGION, 2020–2027 (USD MILLION)
7.5.2 OTHER VNS APPLICATIONS
TABLE 88 VAGUS NERVE STIMULATION MARKET FOR OTHER VNS APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
7.6 GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION
TABLE 89 GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.6.1 GASTROPARESIS
7.6.1.1 GES treatment reduces hospitalizations for patients affected by gastroparesis
TABLE 90 GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY REGION, 2020–2027 (USD MILLION)
7.6.2 OBESITY
7.6.2.1 Risks associated with gastric bypass to increase preference for GES
TABLE 91 GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY REGION, 2020–2027 (USD MILLION)
7.7 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION
TABLE 92 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.7.1 TREATMENT-RESISTANT DEPRESSION
7.7.1.1 TENS induces relaxed state in patients suffering from treatment-resistant depression
TABLE 93 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY REGION, 2020–2027 (USD MILLION)
7.7.2 OTHER TENS APPLICATIONS
TABLE 94 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR OTHER TENS APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
7.8 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION
TABLE 95 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.8.1 DEPRESSION
7.8.1.1 Increased acceptance among patients to drive demand for TMS
TABLE 96 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2020–2027 (USD MILLION)
7.8.2 MIGRAINE
7.8.2.1 High prevalence of migraine to support market growth
TABLE 97 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY REGION, 2020–2027 (USD MILLION)
7.9 RESPIRATORY ELECTRICAL STIMULATION MARKET, BY APPLICATION
7.9.1 SPINAL CORD INJURY
7.9.1.1 Rising incidence of spinal cord injuries ensures sustained demand for RES
TABLE 98 RESPIRATORY ELECTRICAL STIMULATION MARKET FOR SPINAL CORD INJURY, BY REGION, 2020–2027 (USD MILLION)
8 NEUROMODULATION MARKET, BY REGION (Page No. - 117)
8.1 INTRODUCTION
TABLE 99 NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
8.2 NORTH AMERICA
FIGURE 25 NORTH AMERICA: MARKET SNAPSHOT
TABLE 100 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 101 NORTH AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 102 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 103 NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 104 NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 105 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 106 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 107 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 108 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 109 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 110 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.2.1 US
8.2.1.1 Large number of prominent players makes US the largest market
TABLE 111 US: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 112 US: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 113 US: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.2.2 CANADA
8.2.2.1 Rising healthcare expenditure and increasing disease prevalence will drive demand for neurostimulation
TABLE 114 NEUROLOGICAL CONDITIONS PREVALENT IN CANADA
TABLE 115 CANADA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 116 CANADA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 117 CANADA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3 EUROPE
TABLE 118 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 119 EUROPE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 120 EUROPE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 121 EUROPE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 122 EUROPE: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 123 EUROPE: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 124 EUROPE: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 125 EUROPE: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) TABLE 126 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 127 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 128 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.3.1 GERMANY
8.3.1.1 Favorable government initiatives ensure strong market growth in Germany
TABLE 129 GERMANY: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 130 GERMANY: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 131 GERMANY: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.2 UK
8.3.2.1 High public- and private-sector investments fuel market growth
TABLE 132 UK: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 133 UK: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 134 UK: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Availability of insurance and favorable healthcare reforms contribute to growth
TABLE 135 FRANCE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 136 FRANCE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 FRANCE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.4 ITALY
8.3.4.1 Easy access to healthcare services makes Italy a lucrative market
TABLE 138 ITALY: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 139 ITALY: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 140 ITALY: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.5 SPAIN
8.3.5.1 Growing government initiatives may support market growth in Spain
TABLE 141 SPAIN: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 142 SPAIN: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 143 SPAIN: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.6 REST OF EUROPE
TABLE 144 PERCENTAGE OF POPULATION AGED 65 YEARS OR OVER, 2019 VS. 2050
TABLE 145 REST OF EUROPE: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 146 REST OF EUROPE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 147 REST OF EUROPE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: MARKET SNAPSHOT
TABLE 148 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 149 ASIA PACIFIC: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 150 ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 151 ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 152 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 153 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 154 ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 155 ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 156 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 157 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 158 ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.4.1 JAPAN
8.4.1.1 Japan dominates the APAC market for neuromodulation
TABLE 159 JAPAN: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 160 JAPAN: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 161 JAPAN: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.2 CHINA
8.4.2.1 Growing geriatric population will favor market growth in China
TABLE 162 CHINA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 163 CHINA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 164 CHINA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.3 INDIA
8.4.3.1 Improvements in healthcare infrastructure in the country will support market
TABLE 165 INDIA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 166 INDIA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 167 INDIA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.4 REST OF ASIA PACIFIC
TABLE 168 REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 169 REST OF ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 170 REST OF ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.5 REST OF THE WORLD
TABLE 171 REST OF THE WORLD: MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 172 REST OF THE WORLD: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 173 REST OF THE WORLD: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 174 REST OF THE WORLD: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 175 REST OF THE WORLD: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 176 REST OF THE WORLD: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 177 REST OF THE WORLD: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 178 REST OF THE WORLD: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 179 REST OF THE WORLD: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 180 REST OF THE WORLD: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 181 REST OF THE WORLD: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.5.1 LATIN AMERICA
8.5.1.1 Latin America holds largest share of neuromodulation market in RoW
TABLE 182 LATIN AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 183 LATIN AMERICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 184 LATIN AMERICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.5.2 MIDDLE EAST & AFRICA
8.5.2.1 High cost of neuromodulation to hamper market growth
TABLE 185 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 186 MIDDLE EAST & AFRICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 187 MIDDLE EAST & AFRICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
9 COMPETITIVE LANDSCAPE (Page No. - 158)
9.1 OVERVIEW
9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
TABLE 188 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
9.3 REVENUE SHARE ANALYSIS
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN NEUROMODULATION MARKET
9.4 MARKET SHARE ANALYSIS
TABLE 189 MARKET: DEGREE OF COMPETITION
9.5 COMPANY EVALUATION MATRIX
9.5.1 STARS
9.5.2 EMERGING LEADERS
9.5.3 PERVASIVE PLAYERS
9.5.4 PARTICIPANTS
FIGURE 28 COMPANY EVALUATION MATRIX: NEUROMODULATION MARKET
9.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS
9.6.1 PROGRESSIVE COMPANIES
9.6.2 STARTING BLOCKS
9.6.3 RESPONSIVE COMPANIES
9.6.4 DYNAMIC COMPANIES
FIGURE 29 COMPANY EVALUATION MATRIX FOR SMES/START-UPS: NEUROMODULATION MARKET
9.7 COMPANY FOOTPRINT ANALYSIS
TABLE 190 OVERALL FOOTPRINT OF COMPANIES
TABLE 191 REGIONAL FOOTPRINT OF COMPANIES
TABLE 192 TYPE FOOTPRINT OF COMPANIES
9.8 COMPETITIVE BENCHMARKING
TABLE 193 NEUROMODULATION MARKET: DETAILED LIST OF KEY START-UPS/SMES
9.9 COMPETITIVE SCENARIO
9.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 194 KEY PRODUCT LAUNCHES & APPROVALS
9.9.2 DEALS
TABLE 195 KEY DEALS
9.9.3 OTHER DEVELOPMENTS
TABLE 196 OTHER KEY DEVELOPMENTS
10 COMPANY PROFILES (Page No. - 170)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1 KEY PLAYERS
10.1.1 MEDTRONIC PLC
TABLE 197 MEDTRONIC PLC: BUSINESS OVERVIEW
FIGURE 30 MEDTRONIC PLC: COMPANY SNAPSHOT (2021)
10.1.2 BOSTON SCIENTIFIC CORPORATION
TABLE 198 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
FIGURE 31 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2021)
10.1.3 ABBOTT LABORATORIES
TABLE 199 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
10.1.4 LIVANOVA PLC
TABLE 200 LIVANOVA PLC: BUSINESS OVERVIEW
FIGURE 33 LIVANOVA PLC: COMPANY SNAPSHOT (2021)
10.1.5 NEVRO CORPORATION
TABLE 201 NEVRO CORPORATION: BUSINESS OVERVIEW
FIGURE 34 NEVRO CORPORATION: COMPANY SNAPSHOT (2021)
10.1.6 NEUROSIGMA, INC.
TABLE 202 NEUROSIGMA, INC.: BUSINESS OVERVIEW
10.1.7 NEUROPACE, INC.
TABLE 203 NEUROPACE, INC.: BUSINESS OVERVIEW
FIGURE 35 NEUROPACE, INC.: COMPANY SNAPSHOT (2021)
10.1.8 SOTERIX MEDICAL INC.
TABLE 204 SOTERIX MEDICAL INC.: BUSINESS OVERVIEW
10.1.9 SYNAPSE BIOMEDICAL INC.
TABLE 205 SYNAPSE BIOMEDICAL INC.: BUSINESS OVERVIEW
10.1.10 ALEVA NEUROTHERAPEUTICS SA
TABLE 206 ALEVA NEUROTHERAPEUTICS SA: BUSINESS OVERVIEW
10.1.11 THERANICA BIO-ELECTRONICS LTD.
TABLE 207 THERANICA BIO-ELECTRONICS LTD.: BUSINESS OVERVIEW
10.1.12 NEURONETICS
TABLE 208 NEURONETICS: BUSINESS OVERVIEW
FIGURE 36 NEURONETICS: COMPANY SNAPSHOT (2021)
10.1.13 BIONESS
TABLE 209 BIONESS: BUSINESS OVERVIEW
10.1.14 BIOINDUCTION
TABLE 210 BIOINDUCTION: BUSINESS OVERVIEW
10.2 OTHER PLAYERS
10.2.1 GIMER MEDICAL
10.2.2 GTX MEDICAL
10.2.3 HELIUS MEDICAL TECHNOLOGIES
10.2.4 MICROTRANSPONDER
10.2.5 BLUEWIND MEDICAL
10.2.6 ELECTROCORE, INC.
10.2.7 RENISHAW PLC
10.2.8 TVNS TECHNOLOGIES GMBH
10.2.9 BIOWAVEGO USA
10.2.10 CARDIONOMIC, INC.
10.2.11 SALUDA MEDICAL PTY LTD.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX (Page No. - 207)
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 AVAILABLE CUSTOMIZATIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the neuromodulation market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Neuromodulation Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the neuromodulation market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the neuromodulation market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Market Size: Top-Down Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the global neuromodulation market on the basis of type, application, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall neuromodulation market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to five main regions—North America, Europe, the Asia Pacific, and the Rest of the World
- To strategically profile key players and comprehensively analyze their product portfolios, market positions, and core competencies2
- To track and analyze competitive developments such as acquisitions, product launches & approvals, agreements, and partnerships in the neuromodulation market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Country Information
- Neuromodulation market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, and Rest of the World
Company profiles
- Additional five company profiles of players operating in the neuromodulation market.
Neurostimulation Products Market Impact
- Healthcare: The healthcare industry is the primary market for neurostimulation products. Neurostimulation devices are used to treat a range of neurological disorders, such as chronic pain, Parkinson's disease, epilepsy, and depression. The growing demand for neurostimulation products is expected to drive growth in the healthcare industry.
- Medical devices: Neurostimulation products are a type of medical device, and the growth of the neurostimulation market is expected to impact the medical device industry. Companies that manufacture neurostimulation devices will likely see an increase in demand for their products, leading to growth in the medical device market.
- Pharmaceuticals: While neurostimulation products are not a replacement for pharmaceuticals, they can be used in conjunction with medications to treat neurological disorders. The growth of the neurostimulation market may impact the pharmaceutical industry as patients may require fewer medications or may need to take them for shorter periods.
- Research and development: The growth of the neurostimulation market may drive increased investment in research and development for new and improved neurostimulation products. This could lead to innovations in the field and the development of new products with better efficacy and fewer side effects.
- Technology: Neurostimulation products rely on advanced technology, such as wireless communication and miniaturized electronics. As the neurostimulation market grows, there may be an increase in demand for these types of technologies, which could impact the technology industry.
Top Players in Neurostimulation Products Market
- Medtronic: Medtronic is a leading player in the neurostimulation products market, offering a range of products for the treatment of chronic pain, movement disorders, and other neurological conditions. Medtronic's neurostimulation products include spinal cord stimulation systems, deep brain stimulation systems, and sacral neuromodulation systems.
- Abbott Laboratories: Abbott Laboratories is another major player in the neurostimulation products market, offering a range of products for the treatment of chronic pain, Parkinson's disease, and other neurological conditions. Abbott's neurostimulation products include spinal cord stimulation systems, deep brain stimulation systems, and peripheral nerve stimulation systems.
- Boston Scientific: Boston Scientific is a global medical technology company that offers a range of neurostimulation products for the treatment of chronic pain, Parkinson's disease, and other neurological conditions. Boston Scientific's neurostimulation products include spinal cord stimulation systems and deep brain stimulation systems.
- Nevro: Nevro is a medical technology company that specializes in the development of high-frequency spinal cord stimulation systems for the treatment of chronic pain. Nevro's neurostimulation products use a proprietary waveform to provide pain relief without the tingling or buzzing sensations associated with traditional spinal cord stimulation systems.
- LivaNova: LivaNova is a medical technology company that offers a range of neurostimulation products for the treatment of epilepsy, depression, and other neurological conditions. LivaNova's neurostimulation products include vagus nerve stimulation systems and deep brain stimulation systems.
Future Use Cases of Neurostimulation Products Market along with commentary of Adaption, Market Potential and Risk
- Chronic Pain Management: Neurostimulation devices have been used to treat chronic pain conditions such as neuropathic pain and complex regional pain syndrome. The market potential for this application is significant as chronic pain affects millions of people worldwide, and neurostimulation offers a non-invasive alternative to traditional pain management methods. The potential risk is the cost of the devices and the lack of reimbursement in some regions.
- Epilepsy Treatment: Neurostimulation devices are being studied for the treatment of epilepsy, a neurological disorder characterized by recurrent seizures. The market potential for this application is significant as epilepsy affects millions of people worldwide, and neurostimulation offers a potential alternative to medication and surgery. The potential risk is the lack of long-term data on the safety and efficacy of neurostimulation devices for epilepsy treatment.
- Parkinson's Disease Treatment: Neurostimulation devices have been used to treat the motor symptoms of Parkinson's disease, such as tremors and stiffness. The market potential for this application is significant as Parkinson's disease is a prevalent neurological disorder, and neurostimulation offers a non-invasive alternative to medication and surgery. The potential risk is the cost of the devices and the lack of long-term data on the safety and efficacy of neurostimulation devices for Parkinson's disease treatment.
- Depression Treatment: Neurostimulation devices, such as transcranial magnetic stimulation (TMS), are being used to treat depression. The market potential for this application is significant as depression is a prevalent mental health disorder, and neurostimulation offers a non-invasive alternative to medication and psychotherapy. The potential risk is the lack of long-term data on the safety and efficacy of neurostimulation devices for depression treatment.
- Sleep Disorders Treatment: Neurostimulation devices are being studied for the treatment of sleep disorders, such as sleep apnea and insomnia. The market potential for this application is significant as sleep disorders are prevalent, and neurostimulation offers a potential alternative to medication and continuous positive airway pressure (CPAP) machines. The potential risk is the lack of long-term data on the safety and efficacy of neurostimulation devices for sleep disorders treatment.
Future Hypothetic Growth Opportunities and Challenges in Neurostimulation Products Market
Growth Opportunities in Neurostimulation Products Market:
- Increasing prevalence of neurological disorders such as Parkinson's disease, epilepsy, and chronic pain, which will drive demand for neurostimulation products.
- Advancements in technology, such as wireless connectivity and miniaturization, which will enable more targeted and personalized treatment options.
- Growing demand for non-invasive and minimally invasive treatment options.
- Increasing adoption of neurostimulation products by healthcare professionals due to their effectiveness and safety.
- Expanding applications of neurostimulation products beyond traditional neurological disorders, such as in the treatment of obesity and depression.
Challenges in Neurostimulation Products Market:
- High cost of neurostimulation products, which may limit their adoption and accessibility.
- Limited reimbursement coverage for neurostimulation procedures in some regions.
- Risks associated with implantable devices, such as infection, migration, and malfunction.
- Competition from alternative therapies and treatments, such as pharmacological and behavioral therapies.
- Regulatory challenges related to the approval and commercialization of neurostimulation products.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Generating Response ...
Growth opportunities and latent adjacency in Neuromodulation Market